| US 7,514,080 B2 | ||
| Drug conjugate composition | ||
| Godfrey Amphlett, Cambridge, Mass. (US); Wei Zhang, Cambridge, Mass. (US); and Michael Fleming, Londonderry, N.H. (US) | ||
| Assigned to ImmunoGen, Inc., Waltham, Mass. (US) | ||
| Filed on Sep. 14, 2006, as Appl. No. 11/520,878. | ||
| Application 11/520878 is a division of application No. 10/846129, filed on May 14, 2004, granted, now 7,374,762. | ||
| Claims priority of provisional application 60/470550, filed on May 14, 2003. | ||
| Prior Publication US 2007/0009539 A1, Jan. 11, 2007 | ||
| Int. Cl. A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 39/44 (2006.01) | ||
| U.S. Cl. 424—133.1 [424/141.1; 424/142.1; 424/178.1; 424/184.1; 424/193.1] | 102 Claims |
| 1. A composition comprising (i) about 0.1 mg/mL to about 5 mg/mL of a conjugate comprising humanized antibody huC242 that binds to CANAG wherein the antibody is chemically coupled to a maytansinoid that is N2′-deacetyl-N2′-(3-mercapto-1-oxopropyl)-maytansine (DM1) or N2′-deacetyl-N2′-(4-mercapto-4-methyl-1-oxopentyl)-maytansine (DM4), (ii) about 2 mM to about 50 mM of a buffering agent selected from the group consisting of sodium citrate, sodium acetate, and sodium succinate, (iii) polysorbate 20 or polysorbate 80 that is about 0.002% to about 0.1% of the total volume of the composition, (iv) about 50 mM to about 500 mM sodium chloride, and (v) water, wherein the composition has a pH of about 5-6. |